Chantix Personal Injury Lawsuits
A few years ago, smokers across the nation were excited about a new drug that promised to help them quit smoking. The drug allegedly eased nicotine cravings with few side effects. However, after the drug Chantix was approved in May 2006, many people experienced extreme side effects ranging from memory loss and unusual behavior, to psychological problems that caused suicides and suicidal thoughts.
Pfizer, the maker of Chantix, never warned consumers about these possible Chantix psychiatric side effects and the harms that could be suffered by users. Instead, the company released information about how the drug blocked nicotine receptor sites in the brain and allowed smokers an easy way to quit without uncomfortable withdrawal symptoms.
Most users did agree that they no longer cared about smoking, but many also felt overall feelings of ambivalence towards most things in life. Many people experienced moody tendencies and behavioral problems after using the drug. Some even suffered severe self-inflicted injuries and death as a result of suicide after taking Chantix.
In 2008 the FDA announced that warnings about these psychological side effects and the possible risk of suicide would be added to labels on the drug. However, many users had already suffered injury because of taking the drug and some users even reported that symptoms continued after they stopped taking Chantix. This has led to numerous Chantix pharmaceutical defect lawsuits because the makers of pharmaceuticals and all products have a duty to warn consumers about possible harms associated with using their products. The failure to do so can result in the company being liable for harms suffered by consumers of such products.
If you or a loved one has suffered harmful side effects from taking Chantix or any other medication, call the personal injury lawyers at Page || Cagle for a free consultation at 314.322.8515 or toll free at 1.800.500.INJURY (4658). You can also email me at john@pagecagle.com or visit www.injuredclient.com for more information.
